BRPI0811142A2 - Prevenção e tratamento de condições oculares associadas a complementos - Google Patents

Prevenção e tratamento de condições oculares associadas a complementos

Info

Publication number
BRPI0811142A2
BRPI0811142A2 BRPI0811142-1A2A BRPI0811142A BRPI0811142A2 BR PI0811142 A2 BRPI0811142 A2 BR PI0811142A2 BR PI0811142 A BRPI0811142 A BR PI0811142A BR PI0811142 A2 BRPI0811142 A2 BR PI0811142A2
Authority
BR
Brazil
Prior art keywords
prevention
treatment
eye conditions
complementary eye
complementary
Prior art date
Application number
BRPI0811142-1A2A
Other languages
English (en)
Inventor
Philip Hass
Jianping Yin
Kenneth Katschke
Micah Steffek
Christian Wiesmann
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811142(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0811142A2 publication Critical patent/BRPI0811142A2/pt
Publication of BRPI0811142A8 publication Critical patent/BRPI0811142A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
BRPI0811142A 2007-05-23 2008-05-22 prevenção e tratamento de condições oculares associadas a complementos BRPI0811142A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (2)

Publication Number Publication Date
BRPI0811142A2 true BRPI0811142A2 (pt) 2014-12-23
BRPI0811142A8 BRPI0811142A8 (pt) 2018-12-18

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811142A BRPI0811142A8 (pt) 2007-05-23 2008-05-22 prevenção e tratamento de condições oculares associadas a complementos

Country Status (28)

Country Link
US (6) US8007791B2 (pt)
EP (1) EP2152755B1 (pt)
JP (4) JP5416695B2 (pt)
KR (1) KR101540126B1 (pt)
CN (3) CN107096029B (pt)
AR (1) AR066660A1 (pt)
AU (1) AU2008256835B2 (pt)
BR (1) BRPI0811142A8 (pt)
CA (1) CA2683498A1 (pt)
CL (1) CL2008001498A1 (pt)
CY (1) CY1116062T1 (pt)
DK (1) DK2152755T3 (pt)
ES (1) ES2533242T3 (pt)
HK (2) HK1139161A1 (pt)
HR (1) HRP20150281T1 (pt)
IL (2) IL201476A (pt)
MX (1) MX2009012422A (pt)
PE (1) PE20090294A1 (pt)
PH (1) PH12013500992B1 (pt)
PL (1) PL2152755T3 (pt)
PT (1) PT2152755E (pt)
RS (1) RS53901B1 (pt)
RU (2) RU2522976C2 (pt)
SG (1) SG10201401404RA (pt)
SI (1) SI2152755T1 (pt)
TW (2) TWI419704B (pt)
WO (1) WO2008147883A1 (pt)
ZA (1) ZA200907028B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2026073B1 (en) * 2000-04-29 2016-03-30 University Of Iowa Research Foundation Diagnostics and therapeutics for macular degeneration-related disorders
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
PL2907827T3 (pl) 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CN102203075B (zh) * 2008-09-02 2014-09-10 诺华股份有限公司 二环激酶抑制剂
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
SG173167A1 (en) 2009-01-29 2011-08-29 Forsight Labs Llc Posterior segment drug delivery
EP2427479B1 (en) * 2009-05-07 2018-11-21 The Regents of The University of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
PT2600812T (pt) 2010-08-05 2021-11-09 Forsight Vision4 Inc Aparelho para tratar um olho
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
KR20140027090A (ko) 2011-01-04 2014-03-06 노파르티스 아게 연령-관련 황반 변성 (amd)의 치료에 유용한 인돌 화합물 또는 그의 유사체
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
CN104619698B (zh) 2012-06-28 2016-08-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
EP2867224B1 (en) 2012-06-28 2017-07-26 Novartis AG Pyrrolidine derivatives and their use as complement pathway modulators
EP2867227B1 (en) 2012-06-28 2018-11-21 Novartis AG Complement pathway modulators and uses thereof
BR112015000578A2 (pt) 2012-07-12 2017-06-27 Novartis Ag moduladores da via do complemento e usos dos mesmos
US9334332B2 (en) 2012-07-25 2016-05-10 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies
US9255155B2 (en) 2013-01-31 2016-02-09 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of treating cancer
EP2978393B1 (en) 2013-03-28 2023-12-27 ForSight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
MX2016001854A (es) 2013-08-12 2016-09-06 Genentech Inc Composiciones y metodo para tratar condiciones asociadas con el complemento.
US20160237146A1 (en) * 2013-10-07 2016-08-18 Massachusetts Eye And Ear Infirmary Methods of Preventing or Reducing Photoreceptor Cell Death
WO2015061658A1 (en) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
CA2944712A1 (en) * 2014-05-01 2015-11-05 Genentech, Inc. Anti-factor d antibody variants and uses thereof
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
CA2998500A1 (en) * 2015-09-23 2017-03-30 Sangamo Therapeutics, Inc. Htt repressors and uses thereof
CN108472382A (zh) * 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
WO2017075212A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-htra1 antibodies and methods of use thereof
WO2017075173A2 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibodies and conjugates
EP3368682B1 (en) 2015-10-30 2019-12-11 H. Hoffnabb-La Roche Ag Methods of measuring factor d activity and potency of factor d inhibitors
EP3394089B1 (en) * 2015-12-23 2021-07-28 eleva GmbH Polypeptides for inhibiting complement activation
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL268601B2 (en) * 2017-02-10 2024-07-01 Univ Pennsylvania Antibodies against factor D and their uses
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
EP3999626A4 (en) * 2019-07-18 2023-11-22 Pandorum Technologies Private Limited PROCESSES FOR CULTURE OF STEM CELLS TO OBTAIN PRODUCTS AND THEIR MODES OF PRODUCTION

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2000037638A2 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
WO2001004311A1 (en) 1999-07-07 2001-01-18 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2000036102A2 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20050197285A1 (en) 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
PT1481989E (pt) 1997-11-21 2008-08-08 Genentech Inc Antigénios relacionados com a-33 e suas utilizações farmacológicas
US7282565B2 (en) 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
JP2002502589A (ja) 1998-02-09 2002-01-29 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４５個のヒト分泌タンパク質
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
SI2033659T1 (sl) * 1998-02-20 2014-03-31 Genentech, Inc. Inhibitorji komplementne aktivacije
DK1490386T3 (da) 1998-03-10 2008-12-15 Genentech Inc Nyt polypeptid og nukleinsyrer kodende for dette
AU5587799A (en) 1998-08-27 2000-03-21 Incyte Pharmaceuticals, Inc. Protein transport-associated molecules
DK1140175T3 (da) * 1998-12-21 2006-08-14 Ludwig Inst Cancer Res Antistoffer mod trunkeret VEGF-D og anvendelser deraf
CA2362427A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CZ303128B6 (cs) 1999-03-11 2012-04-18 Laboratoires Serono Sa Adhezní molekula 1 regulovaná konfluencí CRAM-1, její kódující nukleová kyselina, protilátky a použití
US6642353B1 (en) 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
WO2001036102A1 (fr) 1999-11-02 2001-05-25 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Procede pour nettoyer un liquide des particules ferromagnetiques et dispositif correspondant
JP2003514541A (ja) 1999-11-19 2003-04-22 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
EP1686134A3 (en) 1999-12-01 2006-08-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2001271973A1 (en) 2000-07-20 2002-02-05 Kevin P. Baker Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2003258714A1 (en) 2002-09-06 2004-03-29 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
WO2007056227A2 (en) * 2005-11-04 2007-05-18 Genentech, Inc. Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
PL2907827T3 (pl) * 2006-11-02 2019-03-29 Genentech, Inc. Humanizowane przeciwciała przeciw czynnikowi D i ich zastosowanie
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
TW201417829A (zh) 2014-05-16
HK1139161A1 (en) 2010-09-10
KR101540126B1 (ko) 2015-07-28
RS53901B1 (en) 2015-08-31
TW200904471A (en) 2009-02-01
AU2008256835B2 (en) 2013-08-01
EP2152755B1 (en) 2014-12-31
PT2152755E (pt) 2015-04-01
RU2009147744A (ru) 2011-06-27
SI2152755T1 (sl) 2015-05-29
US20130302333A1 (en) 2013-11-14
TWI419704B (zh) 2013-12-21
RU2014113046A (ru) 2015-10-10
RU2522976C2 (ru) 2014-07-20
US20180079826A1 (en) 2018-03-22
IL201476A (en) 2016-11-30
IL201476A0 (en) 2010-05-31
CY1116062T1 (el) 2017-02-08
WO2008147883A8 (en) 2013-05-23
SG10201401404RA (en) 2014-08-28
US20130052685A1 (en) 2013-02-28
JP2014087346A (ja) 2014-05-15
KR20100033973A (ko) 2010-03-31
IL248552A0 (en) 2016-12-29
CN107096029B (zh) 2021-02-26
PH12013500992A1 (en) 2016-01-25
JP2010528047A (ja) 2010-08-19
US8007791B2 (en) 2011-08-30
PE20090294A1 (es) 2009-03-27
AU2008256835A1 (en) 2008-12-04
AR066660A1 (es) 2009-09-02
US8268310B2 (en) 2012-09-18
BRPI0811142A8 (pt) 2018-12-18
WO2008147883A1 (en) 2008-12-04
US20110282034A1 (en) 2011-11-17
JP2016145205A (ja) 2016-08-12
DK2152755T3 (en) 2015-03-02
US20090181017A1 (en) 2009-07-16
HK1207327A1 (en) 2016-01-29
US8497094B2 (en) 2013-07-30
CA2683498A1 (en) 2008-12-04
CN101754980A (zh) 2010-06-23
JP2017197577A (ja) 2017-11-02
ZA200907028B (en) 2010-12-29
CN104367999A (zh) 2015-02-25
US20160272726A1 (en) 2016-09-22
CL2008001498A1 (es) 2009-06-12
MX2009012422A (es) 2009-12-04
PH12013500992B1 (en) 2016-01-25
ES2533242T3 (es) 2015-04-08
JP5416695B2 (ja) 2014-02-12
PL2152755T3 (pl) 2015-06-30
HRP20150281T1 (hr) 2015-04-10
CN101754980B (zh) 2014-10-29
EP2152755A1 (en) 2010-02-17
CN107096029A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
BRPI0811142A2 (pt) Prevenção e tratamento de condições oculares associadas a complementos
PL2118300T3 (pl) Zapobieganie i leczenie synukleinopatii i amyloidozy
EP2020970A4 (en) TREATMENT OF THE EYE
DK2114447T3 (da) Forebyggelse og behandling af subkliniks pcvd
BRPI0817082A2 (pt) Implantes lacrimais e métodos relacionados
BRPI0811265A2 (pt) Tratamento de sinucleinopatias
EP2046349A4 (en) TREATMENT OF EXCESSIVE NEOVASCULARIZATION
BRPI0811870A2 (pt) Tratamento e prevenção de influenza
BRPI0816690A2 (pt) derivados 1-amino-alquilciclohexano para tratamento e a prevenção da perda da audição
BRPI0817267A2 (pt) Prevenção de alergia em desmame
BRPI1013004A2 (pt) "elementos de filtro e conjunto de filtro"
HK1184169A1 (zh) 共核蛋白病和致澱粉樣病的預防和治療
ZA200806505B (en) Treatment of HIV
BRPI0716576A2 (pt) Tratamento e prevenção de fibrose intestinal
ZA200905104B (en) Prevention of allergic sensitization
GB0723100D0 (en) Treatment of HFnEF
GB0724970D0 (en) Treatment and prevention of nuerodegenerative diseases
BRPI0716580A2 (pt) Tratamento de distúrbios fibrosantes
GB0811950D0 (en) Disease prevention and treatment
GB0601091D0 (en) The Treatment Of Ocular Conditions
GB0716577D0 (en) Treatment and prevention of neurodegenerative diseases
GB0619506D0 (en) Increasing of intelligence and or treatment of mental retardation
GB0625602D0 (en) Treatment of sialorrhoea

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]